Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2
Sponsor: Materia Medica Holding
This PHASE3 trial investigates Immunization Against COVID-19 and is currently completed. Materia Medica Holding leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Dec 2021 — May 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Materia Medica Holding
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgorod, Russia , Izhevsk, Russia , Kaliningrad, Russia , Kazan', Russia , Kirov, Russia , Krasnodar, Russia , Moscow, Russia , Nizhny Novgorod, Russia , Penza, Russia , Rostov-on-Don, Russia and 7 more locations